QTTB

Q32 Bio Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-10

Figures on this page computed 2026-11-08 12:33 UTC

Last close

8.97USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-10

3.8xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
186.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-05
The filing itself
55.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
-62.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
0.37Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

4.66x

-0.60x

0.53x

0.46x

0.07x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales4.66x
Its own average over 8 years, 11.5M.
Profit-0.60x
Its own average over 10 years, -49.9M.
Free cash flow0.53x
Its own average over 10 years, -63.2M.
Debt0.46x
Its own average over 2 years, 33.1M.
Price0.07x
Its own average over 9 years, 131. Market data, 2026-11-04

Sales is furthest from its own average, at 4.66 times.

Sales is 4.66 times its own 8-year average; Profit is -0.60 times its own 10-year average; Free cash flow is 0.53 times its own 10-year average; Debt is 0.46 times its own 2-year average; Price is 0.07 times its own 9-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales against its own 8-year average4.66
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
The filing itself
Profit against its own 10-year average-0.60
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
The filing itself
Free cash flow against its own 10-year average0.53
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
The filing itself
Debt against its own 2-year average0.46
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099339
Reported in
USD
The filing itself
Price against its own 9-year average0.07Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD